EUVIMEDEUVIMED entdecken
Crossref

Beyond a synthetic lethal pair: The atorvastatin-gefitinib combination as a testable model for cross-pillar therapy in colorectal cancer

Bin Chen, Fan Chen, Lei-Tao Sun, Xin-Lei Zhou, Kai-Bo Guo

World Journal of Gastrointestinal Oncology · 15.11.2026 · 18 (11)

DOI: 10.4251/wjgo.120407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastrointestinal Oncology, online erschienen am 15.11.2026. Verfasst von Bin Chen und 4 weiteren Autor:innen. Die Arbeit nennt 60 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We read with great interest the article by Huang and Ma which reported a synthetic lethal interaction between 3-hydroxy-3-methylglutaryl-CoA reductase and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta in colorectal cancer (CRC) using atorvastatin and gefitinib. This opinion review proposes an extended conceptual framework to interpret the synergy reported therein. We argue that this treatment may involve a cross-pillar interaction between sustained proliferative signaling, targeted by the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, and metabolic reprogramming, affected by cholesterol synthesis blockade through atorvastatin. This two-pronged pressure may limit the adaptive capacity of tumor cells and help explain the anti-proliferative and pro-autophagy effects reported. The AMP-activated protein kinase-sterol regulatory element-binding protein 1 node identified in the original study may serve as an integrative hub linking these pillars. Accumulating preclinical evidence from various cancers suggests that sterol regulatory element-binding protein family members can connect oncogenic signaling and metabolic adaptation. However, available data remain mainly from in vitro and xenograft models. This study may provide insight into a CRC-centered, testable cross-pillar framework rather than a broadly validated therapeutic paradigm. Future studies should assess patient-derived models, predictive biomarkers, safety, efficacy and the context-dependence of this strategy in CRC.

Zitieren

APA

Chen, B., Chen, F., Sun, L., Zhou, X., & Guo, K. (2026). Beyond a synthetic lethal pair: The atorvastatin-gefitinib combination as a testable model for cross-pillar therapy in colorectal cancer. World Journal of Gastrointestinal Oncology, 18(11). https://doi.org/10.4251/wjgo.120407

Vancouver

Chen B, Chen F, Sun L, Zhou X, Guo K. Beyond a synthetic lethal pair: The atorvastatin-gefitinib combination as a testable model for cross-pillar therapy in colorectal cancer. World Journal of Gastrointestinal Oncology. 2026;18(11). doi:10.4251/wjgo.120407

BibTeX
@article{Chen2026,
  author = {Chen, Bin and Chen, Fan and Sun, Lei-Tao and Zhou, Xin-Lei and Guo, Kai-Bo},
  title = {Beyond a synthetic lethal pair: The atorvastatin-gefitinib combination as a testable model for cross-pillar therapy in colorectal cancer},
  journal = {World Journal of Gastrointestinal Oncology},
  year = {2026},
  volume = {18},
  number = {11},
  doi = {10.4251/wjgo.120407}
}
Kostenlos starten →